Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep;47(9):2111-2141.
doi: 10.1007/s40618-024-02363-w. Epub 2024 Jul 15.

Inositols and female reproduction disorders: a consensus statement from the working group of the Club of the Italian Society of Endocrinology (SIE)-Women's Endocrinology

Affiliations
Review

Inositols and female reproduction disorders: a consensus statement from the working group of the Club of the Italian Society of Endocrinology (SIE)-Women's Endocrinology

Costanzo Moretti et al. J Endocrinol Invest. 2024 Sep.

Abstract

Purpose: To provide the latest scientific knowledge on the efficacy of inositols for improving reproductive disorders in women with and without polycystic ovary syndrome (PCOS) and to reach a consensus on their potential use through a Delphi-like process.

Methods: A panel of 17 endocrinologists and 1 gynecologist discussed 4 key domains: menses irregularity and anovulation, fertility, pregnancy outcomes, and neonatal outcomes.

Results: A total of eight consensus statements were drafted. Myo-inositol (Myo) supplementation can be used to improve menses irregularities and anovulation in PCOS. Myo supplementation can be used in subfertile women with or without PCOS to reduce the dose of r-FSH for ovarian stimulation during IVF, but it should not be used to increase the clinical pregnancy rate or live birth rate. Myo supplementation can be used in the primary prevention of gestational diabetes mellitus (GDM), but should not be used to improve pregnancy outcomes in women with GDM. Myo can be preconceptionally added to folic acid in women with a previous neural tube defects (NTD)-complicated pregnancy to reduce the risk of NTDs in newborns. Myo can be used during pregnancy to reduce the risk of macrosomia and neonatal hypoglycemia in mothers at risk of GDM.

Conclusion: This consensus statement provides recommendations aimed at guiding healthcare practitioners in the use of inositols for the treatment or prevention of female reproductive disorders. More evidence-based data are needed to definitively establish the usefulness of Myo, the appropriate dosage, and to support the use of D-chiro-inositol (DCI) or a definitive Myo/DCI ratio.

Keywords: Delphi consensus; Fertility; Neonatal outcomes; Ovulation; Pregnancy outcomes.

PubMed Disclaimer

References

    1. Kiani AK, Paolacci S, Calogero AE, Cannarella R, Di Renzo GC, Gerli S, Della Morte C, Busetto GM, De Berbardinis E, Del Giudice F, Stuppia L, Facchinetti F, Dinicola S, Bertelli M (2021) From Myo-inositol to D-chiro-inositol molecular pathways. Eur Rev Med Pharmacol Sci 25:2390–2402. https://doi.org/10.26355/eurrev_202103_25279 - DOI - PubMed
    1. Laganà AS, Rossetti P, Buscema M, La Vignera S, Condorelli RA, Gullo G, Granese R, Triolo O (2016) Metabolism and ovarian function in pcos women: a therapeutic approach with inositols. Int J Endocrinol. https://doi.org/10.1155/2016/6306410 - DOI - PubMed - PMC
    1. Pak Y, Huang LC, Lilley KJ, Larner J (1992) In vivo conversion of [3H]myoinositol to [3H]chiroinositol in rat tissues. J Biol Chem 267:16904–16910 (PMID: 1387397) - DOI - PubMed
    1. Larner J (2002) D-chiro-inositol–its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res 3:47–60. https://doi.org/10.1080/15604280212528 - DOI - PubMed - PMC
    1. Dinicola S, Unfer V, Facchinetti F et al (2021) Inositols: from established knowledge to novel approaches. Int J Mol Sci 22:10575. https://doi.org/10.3390/ijms221910575 - DOI - PubMed - PMC

Publication types

LinkOut - more resources